文献速递主动脉疾病

内分支支架移植物治疗主动脉弓疾病的安全性与疗效:一项系统综述

Safety and Efficacy of Inner Branched Stent-Graft in the Treatment of Aortic Arch Disease: A Systematic Review.
PubMed 文献 · J Endovasc Ther · 2023-08-30

该系统综述纳入19项研究共618例接受内分支胸主动脉腔内修复(bTEVAR)的主动脉弓疾病患者,主要适应证为慢性主动脉夹层继发动脉瘤(38.8%,n=240/618)。汇总技术成功率为97.4±4.4%(95%CI=95.1%-99.5%),术后卒中发生率为10.5%(95%CI=6.8%-14.3%),30天及住院死亡率为5.5%(95%CI=2.6%-9.7%)。作者认为bTEVAR技术成功率高但学习曲线陡峭,术后卒中仍是主要问题,需进一步经验积累和长期随访。

要点

  • bTEVAR汇总技术成功率为97.4±4.4%(95%CI=95.1%-99.5%)。
  • 术后卒中为最常见的早期并发症,发生率为10.5%(95%CI=6.8%-14.3%)。
  • 30天及住院死亡率为5.5%(95%CI=2.6%-9.7%),早期再干预率为6.5%。

核心结论

  • 分支胸主动脉腔内修复是治疗主动脉弓疾病有前景的方法,技术成功率高但学习曲线陡峭;术后卒中仍是主要关注问题,需进一步经验和长期随访以充分阐明其安全性和耐久性。

研究设计与样本

  • 遵循PRISMA声明的系统综述,检索PubMed和OVID Medline数据库1999年1月至2022年7月,纳入19篇文章共618例接受bTEVAR的患者,多数为双分支(63.9%,n=395)。

主要发现

  • 主要治疗指征为慢性主动脉夹层继发动脉瘤(38.8%,n=240/618),平均最大直径为58.3±11.4 mm。
  • 汇总平均技术成功率为97.4±4.4%(95%CI=95.1%-99.5%),分别有2例和3例患者需转为烟囱技术和开放修复。
  • 早期并发症中术后卒中发生率最高(10.5%;95%CI=6.8%-14.3%),30天及住院死亡率为5.5%(95%CI=2.6%-9.7%)。
  • 40例患者(6.5%;95%CI=2.5%-9.5%)需要早期再干预;平均随访20.7±13.5个月期间死亡率为18.2%(n=108/593;95%CI=8.6%-20.6%),其中12例(11.1%)为主动脉相关死亡。
  • 汇总晚期再干预率为9.6%(95%CI=4.8%-14.3%);单分支与双分支bTEVAR的人口学特征和结局比较无显著差异。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 作者指出需要进一步经验和长期随访以充分阐明bTEVAR在高危患者主动脉疾病管理中的安全性和耐久性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To provide a descriptive overview on the contemporary outcomes of thoracic endovascular arch repair with inner branched endoprosthesis (bTEVAR) for the treatment of aortic arch pathologies. METHODS: A comprehensive literature search was performed in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement. Pre-defined search terms were used to interrogate PubMed and OVID Medline databases from January 1999 to July 2022. Patient characteristics, indication for treatment, procedural data, mortality rates, postoperative complications, and reintervention rate during follow-up were evaluated. RESULTS: Nineteen articles were included, encompassing a total of 618 patients who received bTEVAR, most of which were double-branched (63.9%, n=395). The main indication for treatment was aneurysm secondary to chronic aortic dissection (38.8%, n=240/618) with a mean maximum diameter of 58.3±11.4 mm. Pooled mean technical success rate was 97.4±4.4% (95% confidence interval [CI]=95.1%-99.5%); 2 and 3 patients required conversion to chimney technique and open repair, respectively. Among the pooled rates of early complications, postoperative stroke was the highest (10.5%; 95% CI=6.8%-14.3%). Thirty-day and in-hospital mortality rate was 5.5% (95% CI=2.6%-9.7%). Forty patients (6.5%; 95% CI=2.5%-9.5%) required early reintervention. During a mean follow-up of 20.7±13.5 months, the mortality rate was 18.2% (n=108/593; 95% CI=8.6%-20.6%) where 12 (11.1%) were aortic-related. Pooled late reintervention rate was 9.6% (95% CI=4.8%-14.3%). Comparison of demographics and outcomes found no significant difference between single and double bTEVAR. CONCLUSION: Branched thoracic endovascular aortic repair is a promising approach for aortic arch pathologies with a high technical success rate despite a steep learning curve. However, contemporary outcomes reflect that postoperative stroke remains the predominant concern. Further experience and long-term follow-up are required to sufficiently elucidate the safety and durability of bTEVAR in the management of aortic pathologies for high-risk patients.Clinical ImpactThis systematic review summarized the contemporary outcomes of thoracic endovascular aortic repair with different inner branched stent-grafts for the management of aortic arch pathologies. Pooled results from nineteen studies with 618 patients demonstrated a high technical success rate and an acceptable mortality rate. However, postoperative stroke remains the major concern. Long-term follow-up is needed to evaluate its durability.

来源:J Endovasc Ther,查看原文。版权归原作者所有。

引用

  1. Kwan KJS, Li HL, Chan YC, et al. Safety and Efficacy of Inner Branched Stent-Graft in the Treatment of Aortic Arch Disease: A Systematic Review. J Endovasc Ther. 2023. PMID: 37646117. doi:10.1177/15266028231197395

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。